Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters

Database
Country/Region as subject
Language
Publication year range
1.
J Transl Med ; 18(1): 433, 2020 11 12.
Article in English | MEDLINE | ID: mdl-33183332

ABSTRACT

BACKGROUND: Obesity is a chronic low-grade inflammatory disease that is generally characterized by enhanced inflammation in obese adipose tissue (AT). Here, we investigated alterations in gene expression between lean and obese conditions using mRNA-Seq data derived from human purified adipocytes (ACs) and preadipocytes (preACs). RESULTS: Total mRNA-seq data were generated with 27 AC and 21 preAC samples purified from human visceral AT collected during resection surgery in cancer patients, where the samples were classified into lean and obese categories by BMI > 25 kg/m2. We defined four classes of differentially expressed genes (DEGs) by comparing gene expression between (1) lean and obese ACs, (2) lean and obese preACs, (3) lean ACs and lean preACs, and 4) obese ACs and obese preACs. Based on an analysis of comparison 1, numerous canonical obesity-related genes, particularly inflammatory genes including IL-6, TNF-α and IL-1ß, i.e., the genes that are expected to be upregulated in obesity conditions, were found to be expressed at significantly lower levels in obese ACs than in lean ACs. In contrast, some inflammatory genes were found to be expressed at higher levels in obese preACs than lean preACs in the analysis of comparison 2. The analysis of comparisons 3 and 4 showed that inflammatory gene classes were expressed at higher levels in differentiated ACs than undifferentiated preACs under both lean and obese conditions; however, the degree of upregulation was significantly greater for lean than for obese conditions. We validated our observations using previously published microarray transcriptome data deposited in the GEO database (GSE80654). CONCLUSIONS: Taken together, our analyses suggest that inflammatory genes are expressed at lower levels in obese ACs than in lean ACs because lean adipogenesis involves even greater enhancement of inflammatory responses than does obese adipogenesis.


Subject(s)
Adipocytes , Adipose Tissue , Adipogenesis/genetics , Gene Expression , Humans , Obesity/genetics
2.
Int J Mol Sci ; 21(14)2020 Jul 17.
Article in English | MEDLINE | ID: mdl-32709145

ABSTRACT

This study investigated whether the promoter region of DNA methylation positively or negatively regulates tissue-specific genes (TSGs) and if it correlates with disease pathophysiology. We assessed tissue specificity metrics in five human tissues, using sequencing-based approaches, including 52 whole genome bisulfite sequencing (WGBS), 52 RNA-seq, and 144 chromatin immunoprecipitation sequencing (ChIP-seq) data. A correlation analysis was performed between the gene expression and DNA methylation levels of the TSG promoter region. The TSG enrichment analyses were conducted in the gene-disease association network (DisGeNET). The epigenomic association analyses of CpGs in enriched TSG promoters were performed using 1986 Infinium MethylationEPIC array data. A correlation analysis showed significant associations between the promoter methylation and 449 TSGs' expression. A disease enrichment analysis showed that diabetes- and obesity-related diseases were high-ranked. In an epigenomic association analysis based on obesity, 62 CpGs showed statistical significance. Among them, three obesity-related CpGs were newly identified and replicated with statistical significance in independent data. In particular, a CpG (cg17075888 of PDK4), considered as potential therapeutic targets, were associated with complex diseases, including obesity and type 2 diabetes. The methylation changes in a substantial number of the TSG promoters showed a significant association with metabolic diseases. Collectively, our findings provided strong evidence of the relationship between tissue-specific patterns of epigenetic changes and metabolic diseases.


Subject(s)
DNA Methylation , Diabetes Mellitus, Type 2/genetics , Obesity/genetics , Transcriptome , Animals , CpG Islands , Epigenesis, Genetic , Gene Regulatory Networks , Genome, Human , Humans , Organ Specificity/genetics , Promoter Regions, Genetic , Whole Genome Sequencing
3.
Front Genet ; 13: 1008646, 2022.
Article in English | MEDLINE | ID: mdl-36506321

ABSTRACT

Genotype imputation is essential for enhancing the power of association-mapping and discovering rare and indels that are missed by most genotyping arrays. Imputation analysis can be more accurate with a population-specific reference panel or a multi-ethnic reference panel with numerous samples. The National Institute of Health, Republic of Korea, initiated the Korean Reference Genome (KRG) project to identify variants in whole-genome sequences of ∼20,000 Korean participants. In the pilot phase, we analyzed the data from 1,490 participants. The genetic characteristics and imputation performance of the KRG were compared with those of the 1,000 Genomes Project Phase 3, GenomeAsia 100K Project, ChinaMAP, NARD, and TOPMed reference panels. For comparison analysis, genotype panels were artificially generated using whole-genome sequencing data from combinations of four different ancestries (Korean, Japanese, Chinese, and European) and two population-specific optimized microarrays (Korea Biobank Array and UK Biobank Array). The KRG reference panel performed best for the Korean population (R 2 = 0.78-0.84, percentage of well-imputed is 91.9% for allele frequency >5%), although the other reference panels comprised a larger number of samples with genetically different background. By comparing multiple reference panels and multi-ethnic genotype panels, optimal imputation was obtained using reference panels from genetically related populations and a population-optimized microarray. Indeed, the reference panels of KRG and TOPMed showed the best performance when applied to the genotype panels of KBA (R 2 = 0.84) and UKB (R 2 = 0.87), respectively. Using a meta-imputation approach to merge imputation results from different reference panels increased the imputation accuracy for rare variants (∼7%) and provided additional well-imputed variants (∼20%) with comparable imputation accuracy to that of the KRG. Our results demonstrate the importance of using a population-specific reference panel and meta-imputation to assess a substantial number of accurately imputed rare variants.

4.
Article in English | MEDLINE | ID: mdl-32788176

ABSTRACT

INTRODUCTION: Obesity is growing global health concern and highly associated with increased risk of metabolic diseases including type 2 diabetes. We aimed to discover new differential DNA methylation patterns predisposing obesity and prioritize surrogate epigenetic markers in Koreans. RESEARCH DESIGN AND METHODS: We performed multistage epigenome-wide analyses to identify differentially expressed CpGs in obesity using the Illumina HumanMethylationEPIC array (EPIC). Forty-eight CpGs showed significant differences across three phases: 902 whole blood DNAs from two cohorts (phase 1: n=450, phase 2: n=377) and a hospital-based sample (phase 3: n=75). Samples from phase III participants were used to examine whether the 48 CpGs are significant in the fat tissue and influenced gene expression. Furthermore, we investigated the epigenetic effect of CpG loci in childhood obesity (n=94). RESULTS: Seven of the 48 CpGs exhibited similar changes in the fat tissue along with gene expression changes. In particular, hypomethylated CpG (cg13424229) on the GATA1 transcription factor cluster of CPA3 promoter was related to its increased gene expression and showed consistent effect in childhood obesity. Interestingly, subsequent analysis using RNA sequencing data from 21 preadipocytes and 26 adipocytes suggested CPA3 as a potential obesity-related gene. Moreover, expression patterns from RNA sequencing and public Gene Expression Omnibus showed the correlation between CPA3 and type 2 diabetes (T2D) and asthma. CONCLUSIONS: Our finding prioritizes influential genes in obesity and provides new evidence for the role of CPA3 linking obesity, T2D, and asthma.


Subject(s)
DNA Methylation , Diabetes Mellitus, Type 2 , CpG Islands/genetics , DNA Methylation/genetics , Diabetes Mellitus, Type 2/genetics , Epigenome , Genome-Wide Association Study , Humans , Inflammation/genetics , Obesity/genetics , Regulatory Sequences, Nucleic Acid , Republic of Korea
5.
J Cheminform ; 7(Suppl 1 Text mining for chemistry and the CHEMDNER track): S9, 2015.
Article in English | MEDLINE | ID: mdl-25810780

ABSTRACT

BACKGROUND: Chemical and biomedical Named Entity Recognition (NER) is an essential prerequisite task before effective text mining can begin for biochemical-text data. Exploiting unlabeled text data to leverage system performance has been an active and challenging research topic in text mining due to the recent growth in the amount of biomedical literature. We present a semi-supervised learning method that efficiently exploits unlabeled data in order to incorporate domain knowledge into a named entity recognition model and to leverage system performance. The proposed method includes Natural Language Processing (NLP) tasks for text preprocessing, learning word representation features from a large amount of text data for feature extraction, and conditional random fields for token classification. Other than the free text in the domain, the proposed method does not rely on any lexicon nor any dictionary in order to keep the system applicable to other NER tasks in bio-text data. RESULTS: We extended BANNER, a biomedical NER system, with the proposed method. This yields an integrated system that can be applied to chemical and drug NER or biomedical NER. We call our branch of the BANNER system BANNER-CHEMDNER, which is scalable over millions of documents, processing about 530 documents per minute, is configurable via XML, and can be plugged into other systems by using the BANNER Unstructured Information Management Architecture (UIMA) interface. BANNER-CHEMDNER achieved an 85.68% and an 86.47% F-measure on the testing sets of CHEMDNER Chemical Entity Mention (CEM) and Chemical Document Indexing (CDI) subtasks, respectively, and achieved an 87.04% F-measure on the official testing set of the BioCreative II gene mention task, showing remarkable performance in both chemical and biomedical NER. BANNER-CHEMDNER system is available at: https://bitbucket.org/tsendeemts/banner-chemdner.

SELECTION OF CITATIONS
SEARCH DETAIL